Kalaris Therapeutics, Inc.

KLRS Nasdaq CIK: 0001754068

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 400 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922
Mailing Address 400 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922
Phone 650-249-2727
Fiscal Year End 1231
EIN 831971007

Financial Overview

FY2025

$121.74M
Total Assets
$78.81M
Stockholders' Equity
$98.05M
Cash & Equivalents
$-2.85
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 23, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC
8-K Current report of material events March 17, 2026 View on SEC
10-K Annual financial report March 17, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 17, 2026 View on SEC
4 Insider stock transaction report February 17, 2026 View on SEC

Insider Trading

BUY 2 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.